Tenax Therapeutics (TENX) Change in Accured Expenses (2010 - 2026)

Tenax Therapeutics (TENX) has 17 years of Change in Accured Expenses data on file, last reported at $1.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 268.86% year-over-year to $1.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (up 208.93% YoY), and the FY2025 full-year result was -$421000.0, down 180.5% from the prior year.
• Change in Accured Expenses improved to $1.0 million in Q1 2026, from $124000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $1.0 million in Q2 2025 to a low of -$974000.0 in Q3 2025.
• A 5-year average of $59944.1 and a median of $57000.0 in 2024 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses slumped 442.26% in 2023 and surged 1717.54% in 2025, its largest moves.
• Tracing TENX's Change in Accured Expenses over 5 years: stood at $529205.0 in 2022, then jumped by 89.48% to $1.0 million in 2023, then slumped by 44.45% to $557000.0 in 2024, then tumbled by 77.74% to $124000.0 in 2025, then soared by 726.61% to $1.0 million in 2026.
• Business Quant data shows TENX's Change in Accured Expenses at $1.0 million in Q1 2026, $124000.0 in Q4 2025, and -$974000.0 in Q3 2025.